# A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

> **NCT05584332** · PHASE3 · TERMINATED · sponsor: **Shanghai Bovax Biotechnology Co., Ltd.** · enrollment: 3131 (actual)

## Conditions studied

- Cervical Cancer
- Genital Wart
- CIN1
- CIN2
- CIN3
- Vain I
- Vain III
- Vin I
- Vin II
- Vin III
- AIS
- VAIN - Vaginal Intraepithelial Neoplasia 2

## Interventions

- **BIOLOGICAL:** Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05584332
- **Lead sponsor:** Shanghai Bovax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-09
- **Primary completion:** 2023-03-23
- **Final completion:** 2023-03-23
- **Target enrollment:** 3131 (ACTUAL)
- **Why stopped:** Strategic adjustment
- **Last updated:** 2023-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05584332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05584332, "A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05584332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*